Thrombin and antithrombotics

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 2, 1998, Pages 87-91

  Fenton II, John W ^a,b,e   Ofosu, Frederick A ^c   Brezniak, Diane V ^f   Hassouna, Houriai ^d  

^a NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e WADSWORTH CENTER   (United States)

^f NONE

Author keywords

Argatroban; Bivalirudin; Hirudin; Thrombin; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; HEPARIN; HIRUDIN; HIRULOG; THROMBIN;

ALZHEIMER DISEASE; ANGIOGENESIS; ATHEROSCLEROSIS; CONFERENCE PAPER; CORONARY ARTERY THROMBOSIS; EDEMA; FIBRINOLYSIS; HUMAN; INFLAMMATION; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; MITOGENESIS; PRIORITY JOURNAL; STROKE; THROMBOSIS;

EID: 0031916472     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-995828     Document Type: Conference Paper

References (48)

1. Fenton JW II, Fasco MJ, Stackrow AB, Aronson DL, Young AM, Finlayson JS. Human thrombins. Production, evaluation, and properties of α-thrombin. J Biol Chem 1977;252:3587-3598
2. Fenton JW II, Landis B, Walz D, Finlayson J. In: Lundblad RL, Fenton JW II, Mann KG, eds. Chemistry and Biology of Thrombin. Ann Arbor: Ann Arbor Science Publishers 1977: 43-76
3. Fenton JW II. Thrombin specificity. Ann NY Acad Sci 1981;370:468-495
4. Fenton JW II. Thrombin. Ann NY Acad Sci 1986;485:5-15
5. Fenton JW II. Regulation of thrombin generation and functions. Semin Thromb Hemostas 1988;14:234-240
6. Fenton JW II, Ofosu FA, Brezniak DV, Hassouna HI. Understanding thrombin and hemostasis. Hematol/Oncol Clin North Am 1993;7:1107-1119
7. Fenton JW II. Thrombin functions and antithrombotic intervention. Thromb Haemostas 1995;74:493-498
8. Ofosu FA, Liu L, Freedman J. Control mechanisms in thrombin generation. Semin Thromb Hemostas 1996;22:303-308
9. Irwin D, Robertson K, MacGillivray T. Structure and evolution of the bovine prothrombin gene. J Molec Biol 1988;200:31-45
10. Fenton JW II, Bing D. Thrombin active-site regions. Semin Thromb Hemostas 1986;12:200-220
11. Benzakour O, Kanthow C, Lupu F, et al. Prothrombin cleavage by human vascular smooth muscle cells: A potential alternative pathway to the coagulation cascade. J Cell Biochem 1995;59: 514-528
12. Fenton JW II, Ofosu FA, Moon DG, Maragonore JM. Thrombin structure and function. Why thrombin is the primary target for antithrombotics. Blood Coag Fihrinolysis 1991;2:69-75
13. Madura JA, Rookstool M, Wease G. The management of patients on chronic coumadin therapy undergoing subsequent surgical procedures. Am Surg 1994;60:542-547
14. Liem TK, Silver D. Coumadin: principles of use. Semin Vasc Surg 1996;9:354-361
15. Fareed J, Callas DD, Hoppensteadt DA, Jeske W, Walenga JM, Pifarre R. Current developments in anticoagulant and antithrombotic agents. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 1997:95-126
16. Olson ST, Bjork I. Regulation of thrombin activity by antithrombotie and heparin. Semin Thromb Hemostas 1994;20:373-409
17. Pifarre R, Walenga JM, Fareed J. Clinical disadvantages with the use of heparin as an anticoagulant. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 1997:1-7
18. Messmore HL, Upadhyay G, Farid S, Parachuri R, Wehrmacher W, Godwin J. Heparin-induced thrombocytopenia and thrombosis in cardiovascular surgery. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 1997:83-94
19. Fareed J, Jeske W, Hoppensteadt DA, Clarizio R, Walenga JM. Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemostas, 1996;22 (Suppl. I):77-91
20. Fareed J, Hoppensteadt DA. Pharmacology of the low-molecular-weight heparins. Semin Thromb Hemostas 1996;2:13-18
21. Kimball SD. Challenges in the development of orally bioavailable thrombin active site inhibitors. Blood Coag Fibrinolysis 1995;6:511-519
22. Hijikata-Okunomiya A, Okamoto S. A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemostas 1992;18:135-149
23. 2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl]-2- piperidine-caboxylic acid. Biochemistry 1984;23:85-90
24. Matsuo T, Kario K, Kodama K, Okamoto S. Clinical application of the synthetic thrombin inhibitor, Argatroban (MD-805). Semin Thromb Hemostas 1992;18:155-160
25. Lewis BE, Johnson SA, Grossman ED, Wrona LL. Argatroban as an anticoagulant for coronary procedures in patients with HIT antibody. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 1997:301-308
26. Schwarz RP Jr. The preclinical and clinical pharmacology of Novastan (Argatroban). In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 1997;231-249
27. Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemostas 1991;66:141-152
28. Wallis RB. Hirudins: From leeches to man. Thromb Haemostas 1966;22:185-196
29. Witting JI, Brezniak DV, Hayes JR, Fenton JW II. Human α-and γ-thrombin inhibition by recombinant HVI and HV2K47 hirudins. Thromb Res 1991;63:473-479
30. Loscalzo J. Thrombin inhibitors in fibrinolysis. Circulation 1996; 94:863-865
31. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW II. Design and characterization of hirulogs: A novel class of bivalent inhibitors of thrombin. Biochemistry 1990; 29:7095-7101
32. Fenton JW II. Leeches to hirulogs and other thrombin-directed antithrombotics. Hematol/Oncol Clin North Am 1992;6:1121-1129
33. Witting JI, Bourdon P, Brezniak DV, Maragonore JM, Fenton JW II. Thrombin specific inhibition by and slow cleavage of hirulog-I. Biochem J 1992;283:737-743
34. Maraganore J. Thrombin, thrombin inhibitors, and the arterial thrombotic process. Thromb Haemostas 1993;70:208-211
35. Bittl J, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769
36. White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-2161
37. Rade J, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nature Med 1996;2:293-298
38. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW II, Coughlin SR, Owens GK. Thrombin stimulates smooth muscle proliferation by a proteolylic. receptor mediated mechanism. J Clin Invest 1993;91:94-98
39. McNamara CA, Sarembock IJ, Bachhuber BG, et al. Thrombin and vascular smooth muscle cell proliferation: Implications for atherosclerosis and restenosis. Semin Thromb Hemostas 1996; 22:139-144
40. Zacharski LR, Wojtukiewicz ME, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemostas 1992;18:104-116
41. Zacharski LR, Costantini V. Blood coagulation activation in cancer: challenges for cancer treatment. Hämostaseologie 1995; 15:14-20
42. Walz DA, Fenton JW II. The role of thrombin in tumor cell metastasis. Invasion Metastas 1995;14:303-308
43. Fenton JW II, Ofosu FA, Henrikson KP, Brezniak DV, Hassouna HI. Thrombin participation in cancers. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 1997;517-520
44. Ishihara H, Connolly AJ, Zeng D, et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386:502-506
45. Landano AP, Doolittle RF. Studies on synthetic peptides that hind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sties and species differences. Biochemistry 1980;19:1013-1019
46. Coller BA, Anderson K, Weisman HF. New antiplatelet agents: Platelet GP IIb/IIIa antagonists. Thromb Haemostas 1995;74: 302-308
47. Topol E. Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. Am Heart J 1995;130:666-672
48. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag Fibrinolysis 1995;6: S7-S13